Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Tracey Elizabeth Schefter

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Radiation Oncology
Phone720/848-0737

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Campbell WG, Jones BL, Schefter T, Goodman KA, Miften M. An evaluation of motion mitigation techniques for pancreatic SBRT. Radiother Oncol. 2017 May 29. PMID: 28571887.
      View in: PubMed
    2. Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017 May 17. PMID: 28513823.
      View in: PubMed
    3. Benson AB, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, Hawkins W, Iyer R, Jacob R, Karachristos A, Kelley RK, Kim R, Palta M, Park JO, Sahai V, Schefter T, Schmidt C, Sicklick JK, Singh G, Sohal D, Stein S, Tian GG, Vauthey JN, Venook AP, Zhu AX, Hoffmann KG, Darlow S. NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 2017 May; 15(5):563-573. PMID: 28476736.
      View in: PubMed
    4. Olsen JR, Moughan J, Myerson R, Abitbol A, Doncals DE, Johnson D, Schefter TE, Chen Y, Fisher B, Michalski J, Narayan S, Chang A, Crane CH, Kachnic L. Predictors of Radiation Therapy-Related Gastrointestinal Toxicity From Anal Cancer Dose-Painted Intensity Modulated Radiation Therapy: Secondary Analysis of NRG Oncology RTOG 0529. Int J Radiat Oncol Biol Phys. 2017 Jun 01; 98(2):400-408. PMID: 28463160.
      View in: PubMed
    5. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Brachytherapy should not be omitted when treating locally advanced neuroendocrine cervical cancer with definitive chemoradiation therapy. Brachytherapy. 2016 Nov - Dec; 15(6):845-850. PMID: 27720204.
      View in: PubMed
    6. Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecol Oncol. 2016 Nov; 143(2):319-325. PMID: 27640961.
      View in: PubMed
    7. Amini A, Jones BL, Ghosh D, Schefter TE, Goodman KA. Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: Analysis of the National Cancer Data Base. Cancer. 2017 Jan 01; 123(2):228-236. PMID: 27571233.
      View in: PubMed
    8. Jackson MW, Amini A, Jones BL, Rusthoven CG, Schefter TE, Goodman KA. Treatment Selection and Survival Outcomes With and Without Radiation for Unresectable, Localized Intrahepatic Cholangiocarcinoma. Cancer J. 2016 Jul-Aug; 22(4):237-42. PMID: 27441741.
      View in: PubMed
    9. Meguid C, Schulick RD, Schefter TE, Lieu CH, Boniface M, Williams N, Vogel JD, Gajdos C, McCarter M, Edil BH. The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients. Ann Surg Oncol. 2016 Nov; 23(12):3986-3990. PMID: 27342825.
      View in: PubMed
    10. Boniface MM, Wani SB, Schefter TE, Koo PJ, Meguid C, Leong S, Kaplan JB, Wingrove LJ, McCarter MD. Multidisciplinary management for esophageal and gastric cancer. Cancer Manag Res. 2016; 8:39-44. PMID: 27217796; PMCID: PMC4853141.
    11. Amini A, DeWitt PE, Vinogradskiy Y, Rusthoven CG, Altunbas C, Schefter TE, Fisher CM. Should we customize PTV expansions for BMI? Daily cone beam computerized tomography to assess organ motion in postoperative endometrial and cervical cancer patients. Rep Pract Oncol Radiother. 2016 May-Jun; 21(3):195-200. PMID: 27601950; PMCID: PMC5002021 [Available on 05/01/17].
    12. Meguid C, Ryan CE, Edil BH, Schulick RD, Gajdos C, Boniface M, Schefter TE, Purcell WT, McCarter M. Establishing a framework for building multidisciplinary programs. J Multidiscip Healthc. 2015; 8:519-26. PMID: 26664132.
      View in: PubMed
    13. Fisher CM, Schefter TE. Profile of bevacizumab and its potential in the treatment of cervical cancer. Onco Targets Ther. 2015; 8:3425-31. PMID: 26640382; PMCID: PMC4657807.
    14. Schubert L, Liu A, Gan G, Amini A, Hutchison R, Ernest J, Thornton D, Stoehr S, Hinman B, Stuhr K, Westerly D, Schefter T, Fisher C. Practical implementation of quality improvement for high-dose-rate brachytherapy. Pract Radiat Oncol. 2016 Jan-Feb; 6(1):34-43. PMID: 26577008.
      View in: PubMed
    15. Jones BL, Schefter T, Miften M. Adaptive motion mapping in pancreatic SBRT patients using Fourier transforms. Radiother Oncol. 2015 May; 115(2):217-22. PMID: 25890573; PMCID: PMC4468008.
    16. Carlson JA, Rusthoven C, DeWitt PE, Davidson SA, Schefter TE, Fisher CM. Are we appropriately selecting therapy for patients with cervical cancer? Longitudinal patterns-of-care analysis for stage IB-IIB cervical cancer. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):786-93. PMID: 25585782.
      View in: PubMed
    17. Benson AB, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug; 12(8):1152-82. PMID: 25099447.
      View in: PubMed
    18. Gaffney DK, Jhingran A, Portelance L, Viswanathan A, Schefter T, Weidhaas J, Small W. Radiation therapy oncology group gynecologic oncology working group: comprehensive results. Int J Gynecol Cancer. 2014 Jun; 24(5):956-62. PMID: 24819663; PMCID: PMC4808297.
    19. Jackson MW, Rusthoven CG, Fisher CM, Schefter TE. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther. 2014; 7:751-9. PMID: 24876784; PMCID: PMC4037327.
    20. Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun; 4(3):137-44. PMID: 24766678.
      View in: PubMed
    21. Lockhart AC, Reed CE, Decker PA, Meyers BF, Ferguson MK, Oeltjen AR, Putnam JB, Cassivi SD, Montero AJ, Schefter TE. Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051). Ann Oncol. 2014 May; 25(5):1039-44. PMID: 24562448.
      View in: PubMed
    22. Schefter T, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W, Sause W, Gaffney D. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2014 Jan 01; 88(1):101-5. PMID: 24331655.
      View in: PubMed
    23. Altunbas C, Howells C, Proper M, Reddy K, Gan G, DeWitt P, Kavanagh B, Schefter T, Miften M. Evaluation of threshold and gradient based (18)F-fluoro-deoxy-2-glucose hybrid positron emission tomographic image segmentation methods for liver tumor delineation. Pract Radiat Oncol. 2014 Jul-Aug; 4(4):217-25. PMID: 25012829.
      View in: PubMed
    24. Rusthoven CG, Liu AK, Bui MM, Schefter TE, Elias AD, Lu X, Gonzalez RJ. Sarcomas of the aorta: a systematic review and pooled analysis of published reports. Ann Vasc Surg. 2014 Feb; 28(2):515-25. PMID: 24485779.
      View in: PubMed
    25. Vinogradskiy Y, Diot Q, Kavanagh B, Schefter T, Gaspar L, Miften M. Spatial and dose-response analysis of fibrotic lung changes after stereotactic body radiation therapy. Med Phys. 2013 Aug; 40(8):081712. PMID: 23927309.
      View in: PubMed
    26. Jones B, Gan G, Schefter T, Miften M. SU-E-T-412: What Is the Benefit of Fiducial Marker Implantation for Pancreatic SBRT? Med Phys. 2013 Jun; 40(6Part17):299. PMID: 28517682.
      View in: PubMed
    27. Lo SS, Sahgal A, Chang EL, Mayr NA, Teh BS, Huang Z, Schefter TE, Yao M, Machtay M, Slotman BJ, Timmerman RD. Serious complications associated with stereotactic ablative radiotherapy and strategies to mitigate the risk. Clin Oncol (R Coll Radiol). 2013 Jun; 25(6):378-87. PMID: 23375484.
      View in: PubMed
    28. Westerly DC, Schefter TE, Kavanagh BD, Chao E, Lucas D, Flynn RT, Miften M. High-dose MVCT image guidance for stereotactic body radiation therapy. Med Phys. 2012 Aug; 39(8):4812-9. PMID: 22894407.
      View in: PubMed
    29. Howells CC, Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD, Miften M. Normal liver tissue density dose response in patients treated with stereotactic body radiation therapy for liver metastases. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):e441-6. PMID: 22682809.
      View in: PubMed
    30. Diot Q, Kavanagh B, Schefter T, Gaspar L, Stuhr K, Miften M. Regional normal lung tissue density changes in patients treated with stereotactic body radiation therapy for lung tumors. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1024-30. PMID: 22583607.
      View in: PubMed
    31. Stinauer MA, Diot Q, Westerly DC, Schefter TE, Kavanagh BD. Fluorodeoxyglucose positron emission tomography response and normal tissue regeneration after stereotactic body radiotherapy to liver metastases. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):e613-8. PMID: 22494588.
      View in: PubMed
    32. Schefter TE, Winter K, Kwon JS, Stuhr K, Balaraj K, Yaremko BP, Small W, Gaffney DK. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):1179-84. PMID: 22342094.
      View in: PubMed
    33. Schefter TE, Kavanagh BD. Radiation therapy for liver metastases. Semin Radiat Oncol. 2011 Oct; 21(4):264-70. PMID: 21939855.
      View in: PubMed
    34. Amaria R, Schefter TE, Durham J, Pita De Oliveira LO, Kane M. Selective internal radiotherapy in metastatic esophageal adenocarcinoma. Gastrointest Cancer Res. 2011 Sep; 4(5-6):191-3. PMID: 22295134; PMCID: PMC3269141.
    35. Chen YK, Schefter TE, Newman F. Esophageal cancer patients undergoing external beam radiation after placement of self-expandable metal stents: is there a risk of radiation dose enhancement? Gastrointest Endosc. 2011 Jun; 73(6):1109-14. PMID: 21628012.
      View in: PubMed
    36. Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, Robinson W, Chidel M, Glode M, Raben D. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011 Apr 08; 6:34. PMID: 21477295; PMCID: PMC3094365.
    37. Chang DT, Swaminath A, Kozak M, Weintraub J, Koong AC, Kim J, Dinniwell R, Brierley J, Kavanagh BD, Dawson LA, Schefter TE. Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer. 2011 Sep 01; 117(17):4060-9. PMID: 21432842.
      View in: PubMed
    38. Buyyounouski MK, Balter P, Lewis B, D'Ambrosio DJ, Dilling TJ, Miller RC, Schefter T, Tomé W, Harris EE, Price RA, Konski AA, Wallner PE. Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: report of the ASTRO Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010 Sep 01; 78(1):3-10. PMID: 20643514.
      View in: PubMed
    39. Buyyounouski MK, Price RA, Harris EE, Miller R, Tomé W, Schefter T, Parsai EI, Konski AA, Wallner PE. Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee. Int J Radiat Oncol Biol Phys. 2010 Apr; 76(5):1297-304. PMID: 20338473.
      View in: PubMed
    40. Cárdenes HR, Price TR, Perkins SM, Maluccio M, Kwo P, Breen TE, Henderson MA, Schefter TE, Tudor K, Deluca J, Johnstone PA. Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol. 2010 Mar; 12(3):218-25. PMID: 20231127.
      View in: PubMed
    41. Dunlap NE, Cai J, Biedermann GB, Yang W, Benedict SH, Sheng K, Schefter TE, Kavanagh BD, Larner JM. Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):796-801. PMID: 19427740.
      View in: PubMed
    42. Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21. PMID: 19307945.
      View in: PubMed
    43. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, Pugh TJ, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009 Apr 01; 27(10):1579-84. PMID: 19255320.
      View in: PubMed
    44. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, Gaspar LE, Schefter TE. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009 Apr 01; 27(10):1572-8. PMID: 19255321.
      View in: PubMed
    45. Olsen CC, Welsh J, Kavanagh BD, Franklin W, McCarter M, Cardenes HR, Gaspar LE, Schefter TE. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24. PMID: 18990508.
      View in: PubMed
    46. McCammon R, Schefter TE, Gaspar LE, Zaemisch R, Gravdahl D, Kavanagh B. Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2009 Jan 01; 73(1):112-8. PMID: 18786780.
      View in: PubMed
    47. Schwer AL, Ballonoff A, McCammon R, Rusthoven K, D'Agostino RB, Schefter TE. Survival effect of neoadjuvant radiotherapy before esophagectomy for patients with esophageal cancer: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys. 2009 Feb 01; 73(2):449-55. PMID: 18538500.
      View in: PubMed
    48. Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008 Jun; 31(3):264-70. PMID: 18525306.
      View in: PubMed
    49. Small W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, Jhingran A, Portelance L, Schefter T, Iyer R, Varia M, Winter K, Mundt AJ. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008 Jun 01; 71(2):428-34. PMID: 18037584; PMCID: PMC2752724.
    50. Kavanagh BD, Ding M, Schefter TE, Stuhr K, Newman FA. The dosimetric effect of inhomogeneity correction in dynamic conformal arc stereotactic body radiation therapy for lung tumors. J Appl Clin Med Phys. 2006 May 25; 7(2):58-63. PMID: 17533331.
      View in: PubMed
    51. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, McCarter MD, Burri S, Nedzi LA, Sawyer TE, Gaspar LE. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006; 45(7):848-55. PMID: 16982549.
      View in: PubMed
    52. Kelsey CR, Schefter T, Nash SR, Russ P, Barón AE, Zeng C, Gaspar LE. Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. Am J Clin Oncol. 2005 Dec; 28(6):576-80. PMID: 16317267.
      View in: PubMed
    53. Schefter TE, Kavanagh BD, Timmerman RD, Cardenes HR, Baron A, Gaspar LE. A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005 Aug 01; 62(5):1371-8. PMID: 16029795.
      View in: PubMed
    54. Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2. Oncology (Williston Park). 2005 Jun; 19(7):830, 835-6, 838 passim. PMID: 16053033.
      View in: PubMed
    55. Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, part 1. Oncology (Williston Park). 2005 May; 19(6):775-8, 783-4, 788 passim. PMID: 15971452.
      View in: PubMed
    56. Song DY, Kavanagh BD, Benedict SH, Schefter T. Stereotactic body radiation therapy. Rationale, techniques, applications, and optimization. Oncology (Williston Park). 2004 Oct; 18(11):1419-30; discussion 1430, 1432, 1435-6. PMID: 15609470.
      View in: PubMed
    57. Groshong S, Davidson S, Schefter T, Singh M. Ovarian immature teratoma with implants and metastases. Oncology (Williston Park). 2004 Apr; 18(4):474-7. PMID: 15134355.
      View in: PubMed
    58. Kavanagh BD, Timmerman RD, Benedict SH, Wu Q, Schefter TE, Stuhr K, McCourt S, Newman F, Cardinale RM, Gaspar LF. How should we describe the radioblologic effect of extracranial stereotactic radlosurgery: equivalent uniform dose or tumor control probability? Med Phys. 2003 Mar; 30(3):321-4. PMID: 12674231.
      View in: PubMed
    59. Kavanagh BD, Schefter TE, Wu Q, Tong S, Newman F, Arnfield M, Benedict SH, McCourt S, Mohan R. Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol. 2002 Jul; 12(3):260-71. PMID: 12118391.
      View in: PubMed
    60. Schefter TE, Gaspar LE. Triple modality (neoadjuvant chemoradiotherapy followed by surgical resection): is it better than definitive chemoradiation therapy in cancer of the thoracic esophagus? Int J Radiat Oncol Biol Phys. 2002 Feb 01; 52(2):581-2. PMID: 11872309.
      View in: PubMed
    61. Schefter TE, Kavanagh BD, Wu Q, Tong S, Newman F, Mccourt S, Arnfield M, Benedict S, Mohan R. Technical considerations in the application of intensity-modulated radiotherapy as a concomitant integrated boost for locally-advanced cervix cancer. Med Dosim. 2002; 27(2):177-84. PMID: 12074470.
      View in: PubMed
    Schefter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)